Work

Data from Zeroing in on ROS1 Rearrangements in Non–Small Cell Lung Cancer

Year: 2023

Type: other

Abstract: Rimkunas and colleagues report on the development and validation of an immunohistochemical assay evaluating non–small cell lung cancers (NSCLC) for the presence of ROS1 fusions. The diagnostic was validated in a screen of 556 NSCLCs, identifying 9 (1.6%) tumors with oncogenic ROS1 rearrangements. These patients are candidates for ROS1-targeted therapies. Clin Cancer Res; 18(16); 4222–4. ©2012 AACR.

DOI: 10.1158/1078-0432.c.6520916

Authors: Magda Stumpfova, Pasi A. Jänne

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361960875

Cites:

Cited by:

Related to: 10